Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.

NCT00525408 is registered in ClinicalTrials.gov with Cadila Pharnmaceuticals as lead sponsor.

NCT NCT00525408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.
Lead sponsor
Cadila Pharnmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2007
Completion date
January 31, 2013
Enrollment
134 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer